• Rosa Faner, Ruth Tal-Singer, John H Riley, Bartolomé Celli, Jørgen Vestbo, William MacNee, Per Bakke, Peter M A Calverley, Harvey Coxson, Courtney Crim, Lisa D Edwards, Nick Locantore, David A Lomas, Bruce E Miller, Stephen I Rennard, Emiel F M Wouters, Julie C Yates, Edwin K Silverman, Alvar Agusti, and ECLIPSE Study Investigators.
• Fundació Investigació Sanitària Illes Balears (FISIB), Ciber Enfermedades Respiratorias (CIBERES), Barcelona, Catalunya, Spain.
• Thorax. 2014 Jul 1;69(7):666-72.

AbstractThe Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) study was a large 3-year observational controlled multicentre international study aimed at defining clinically relevant subtypes of chronic obstructive pulmonary disease (COPD) and identifying novel biomarkers and genetic factors. So far, the ECLIPSE study has produced more than 50 original publications and 75 communications to international meetings, many of which have significantly influenced our understanding of COPD. However, because there is not one paper reporting the biomarker results of the ECLIPSE study that may serve as a reference for practising clinicians, researchers and healthcare providers from academia, industry and government agencies interested in COPD, we decided to write a review summarising the main biomarker findings in ECLIPSE.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

11 keywords...

hide…